Ipca Laboratories Ltd
Ipca Laboratories Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
What the Q1 FY27 call signalled
2 of 4 strong
The short version
Ipca Laboratories expects overall consolidated business growth of around 14% to 16% for the current financial year FY27, revised upward from earlier guidance of 12% to 13%. - Domestic formulation business grew 13% in Q1 FY27; chronic segment grew 17.2%, acute segment 8.9%, outperforming the market. - Export business grew 34% in Q1 FY27, with generic business growing 27%, and institutional generic business reporting exceptional growth of 107% due to shipment timing. - Unichem portfolio delivered 9% growth, with U.S. Overall consolidated revenue growth guidance for FY27 revised upward to 14%-16% from earlier 12%-13%.
From Ipca Laboratories Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Ipca Laboratories expects overall consolidated business growth of around 14% to 16% for the current financial year FY27, revised upward from earlier guidance of 12% to 13%.
- Domestic formulation business grew 13% in Q1 FY27; chronic segment grew 17.2%, acute segment 8.9%, outperforming the market.
- Export business grew 34% in Q1 FY27, with generic business growing 27%, and institutional generic business reporting exceptional growth of 107% due to shipment timing.
- Unichem portfolio delivered 9% growth, with U.S. business growing 27% and Brazil showing strong 52% growth.
- Ipca projects medium-term EBITDA margin improvement to around 26-30% for Ipca and 25% overall for consolidated entities over 2-3 years.
2 more points from Ipca Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Ipca Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Major investments are focused on the biotech segment, with around 7 candidates in the pipeline and capacity to work on 3-4 products annually.
- Current year planned biotech investment is approximately INR 100 crores for piloting facilities and R&D.
- Additional capacity expansion in biotech may be needed within 1-2 years.
- Capacity expansion is ongoing for European and U.S. markets, including controlled and extended-release formulations at the Pithampur facility.
- New API plants are being built at Dewas and Wardha due to capacity constraints at Ratlam.
- Continuous process improvements are underway, including converting intermediates for better efficiency.
2 more points from Ipca Laboratories Ltd's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Ipca Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Ipca Laboratories Ltd's call on order book
Create a free account to keep reading this call
Ipca Laboratories Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Dec 2025 (Q3 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹2.4K Cr, net profit ₹364 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Ipca Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Ipca Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Ipca Laboratories Ltd Q1 FY27 results?
Ipca Laboratories expects overall consolidated business growth of around 14% to 16% for the current financial year FY27, revised upward from earlier guidance of 12% to 13%. - Domestic formulation business grew 13% in Q1 FY27; chronic segment grew 17.2%, acute segment 8.9%, outperforming the market. - Export business grew 34% in Q1 FY27, with generic business growing 27%, and institutional generic business reporting exceptional growth of 107% due to shipment timing. - Unichem portfolio delivered 9% growth, with U.S. Overall consolidated revenue growth guidance for FY27 revised upward to 14%-16% from earlier 12%-13%.
What is Ipca Laboratories Ltd share price analysis?
Ipca Laboratories Ltd currently shows a below-average growth signal. The stock trades at a P/E of 33.9 with a market cap of ₹46,494 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ipca Laboratories Ltd planning capital expenditure?
Major investments are focused on the biotech segment, with around 7 candidates in the pipeline and capacity to work on 3-4 products annually. - Current year planned biotech investment is approximately INR 100 crores for piloting facilities and R&D. - Additional capacity expansion in biotech may be needed within 1-2 years. - Capacity expansion is ongoing for European and U.S.
Keep Ipca Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.